Stock Alert: Applied DNA Sciences Jumps 50% On Positive COVID-19 Vaccine Data

(RTTNews) - Shares of Applied DNA Sciences, Inc. (APDN) are surging more than 50 percent or $4.51 in Friday's morning trade at $13.50 after the company reported positive preclinical results from its LineaDNA vaccine candidates for COVID-19.

Friday, Applied DNA Sciences said that linear-DNA forms of COVID-19 vaccine candidates under development by its partner Takis Biotech and manufactured by the company yielded strong antibody and T-cell responses even at very low doses of linear DNA, raising the potential of effective dosing empowering global utility.

"We are pleased to report that all five LineaDNA vaccine candidates provoked seroconversion in mice with all animals producing IgG against the SARS-CoV-2 Spike Protein by Day 14 and significantly enhanced responses by Day 38," said Dr. James Hayward, president and CEO of Applied DNA.

The company said it looked forward to supporting further studies by Takis with a goal of entering human trials in early Autumn.

Applied DNA Sciences has traded in a range of $2.52 to 19.69 in the past 52 weeks.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos


    Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

    Learn More